Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more
Innate Pharma (IPHYF) - Total Assets
Latest total assets as of June 2025: $92.94 Million USD
Based on the latest financial reports, Innate Pharma (IPHYF) holds total assets worth $92.94 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Innate Pharma - Total Assets Trend (2005–2024)
This chart illustrates how Innate Pharma’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Innate Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Innate Pharma's total assets of $92.94 Million consist of 77.2% current assets and 22.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.8% |
| Accounts Receivable | $1.64 Million | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Innate Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innate Pharma's current assets represent 77.2% of total assets in 2024, a decrease from 85.6% in 2005.
- Cash Position: Cash and equivalents constituted 59.8% of total assets in 2024, up from 10.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Innate Pharma Competitors by Total Assets
Key competitors of Innate Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Innate Pharma - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Innate Pharma generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Innate Pharma is currently not profitable relative to its asset base.
Innate Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.92 | 1.99 |
| Quick Ratio | 2.21 | 2.84 | 1.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $35.55 Million | $ 73.37 Million | $ 81.34 Million |
Innate Pharma - Advanced Valuation Insights
This section examines the relationship between Innate Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 33.06 |
| Latest Market Cap to Assets Ratio | 1.58 |
| Asset Growth Rate (YoY) | -36.6% |
| Total Assets | $111.06 Million |
| Market Capitalization | $174.96 Million USD |
Valuation Analysis
Above Book Valuation: The market values Innate Pharma's assets above their book value (1.58 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Innate Pharma's assets decreased by 36.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Innate Pharma (2005–2024)
The table below shows the annual total assets of Innate Pharma from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $111.06 Million | -36.61% |
| 2023-12-31 | $175.19 Million | -15.72% |
| 2022-12-31 | $207.86 Million | -22.29% |
| 2021-12-31 | $267.50 Million | -12.99% |
| 2020-12-31 | $307.42 Million | -23.40% |
| 2019-12-31 | $401.36 Million | -11.05% |
| 2018-12-31 | $451.22 Million | +76.93% |
| 2017-12-31 | $255.02 Million | -9.43% |
| 2016-12-31 | $281.58 Million | -7.97% |
| 2015-12-31 | $305.96 Million | +237.36% |
| 2014-12-31 | $90.69 Million | +62.29% |
| 2013-12-31 | $55.88 Million | +15.71% |
| 2012-12-31 | $48.30 Million | -19.65% |
| 2011-12-31 | $60.11 Million | +25.20% |
| 2010-12-31 | $48.01 Million | -25.24% |
| 2009-12-31 | $64.22 Million | +5.52% |
| 2008-12-31 | $60.86 Million | -3.63% |
| 2007-12-31 | $63.15 Million | -8.81% |
| 2006-12-31 | $69.25 Million | +179.63% |
| 2005-12-31 | $24.77 Million | -- |